Date:11/10/2011

s and licenses related to its products, or other companies may develop competing therapies and/or technologies, or health care reform may adversely affect Discovery Labs; risks of legal proceedings, including securities actions and product liability claims; risks relating to health care reform; and other risks and uncertainties described in Discovery Labs' filings with the Securities and Exchange Commission including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto.Condensed Consolidated Statement of Operations
(in thousands, except per share data)Three Months EndedNine Months EndedSeptember 30,September 30(unaudited)(unaudited)2011201020112010Revenue from collaborative arrangement and grants $
-$
-$
582$
-Operating expenses: (1)Research and development3,9814,72713,21613,223General and administrative2,1891,4765,9756,273Total expenses6,1706,20319,19119,496Operating loss(6,170)(6,203)(18,609)(19,496)Change in fair value of common stock warrant liability (1)1,422(365)1,9576,384Other income / (expense), net(3)(16)(12)(323)Net loss $
(4,751)$
(6,584)$
(16,664)$
(13,435)Net loss per common share$
(0.20)$
(0.51)$
(0.75)$
(1.23)Weighted avg. common shares outstanding24,10612,94522,10410,954(1) Material non-cash items include the change in fair value of certain outstanding warrants accounted for as derivative liabilities, and in operating expenses, depreciation and stock-based compensation. For the three and nine months ended September 30, 2011, the charges for depreciation and stock-based compensation were $0.5 million ($0.4 million in R&D and $0.1 million in G&A) and $1.5 million ($1.1 million in R&D and $0.4 million in G&A), respectively.  For the three and nine months ended September 30, 2010, the charges for depreciation and stock-based compensation were $0.6 million ($0.4 million in R&D and $0.2 million in G&A) and $2.1 million ($1.3 million in R&D and $0.8 m
'/>"/>

SOURCE Discovery Laboratories, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
2. Concentric Named Professional Agency of Record for Discovery Labs SURFAXIN(R)
3. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Ion Channel Targets, Booth 5
4. Biotechnology & Drug Discovery Markets Push Up Demand for Lab Automation Products, According to a New Report by Global Industry Analysts
5. Assay Designs(TM), Inc. and the Spinal Muscular Atrophy Foundation Announce Collaboration To Accelerate the Discovery of New Therapeutics for Spinal Muscular Atrophy (SMA)
6. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Assays & Cellular Targets Conference, Booth 11
7. Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration
8. The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline
9. Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline
10. deCODE Discovery Sheds Light on Risk of the Most Common Form of Skin Cancer
11. Global Drug Discovery Technologies Market to Exceed $57 Billion by 2012, According to a New Report by Global Industry Analysts